This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?
by Sanghamitra Saha
Though markets rallied probably on the undervalued status and a still-steady US economy, rising recessionary fears and full-scale trade war risks should brighten the appeal of safer ETFs.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK
Small Caps Taking Charge of the Bulls: 6 ETF Winners YTD
by Sweta Killa
we have presented six top performing small-cap ETFs of the current rally that have gained in double digits and will continue their outperformance.
Top ETFs of Last Week
by Sanghamitra Saha
These ETFs have had a strong last week.
6 Wining ETF Areas From a Late Santa Rally
by Sanghamitra Saha
These sector ETFs have made the most of the start of this Santa Rally.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
5 Small-Cap ETFs & Stocks Crushing Russell 2000
by Sweta Killa
We have presented five ETFs & stocks that have easily crushed the Russell 2000 index this year and are likely to continue their strong performance.